Purple Biotech ( (PPBT) ) just unveiled an update.
Purple Biotech announced its financial results for the fourth quarter and full-year 2024, highlighting significant progress in its clinical-stage programs. The company completed successful trials for CM24 and NT219, demonstrating clinical benefits and identifying potential biomarkers. CM24 showed positive results in a Phase 2 pancreatic cancer trial, leading to plans for a biomarker-driven Phase 2b study. NT219 is advancing into a Phase 2 head and neck cancer trial in collaboration with the University of Colorado. Additionally, the CAPTN-3 platform yielded promising preclinical data, positioning it well in the multi-specific antibody space. Financially, the company reported a decrease in research and development expenses and operating loss compared to the previous year.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company operates in the biotechnology industry and is engaged in the development of oncology assets, including CM24 and NT219, as well as the CAPTN-3 tri-specific platform.
YTD Price Performance: -38.78%
Average Trading Volume: 67,374
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $7.74M
See more insights into PPBT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com